Oct. 4, 2013 -- Stelara, an injectable drug already approved to treat psoriasis, is now also approved to treat psoriatic arthritis. Psoriatic arthritis is an autoimmune disease. The immune system ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi ® ...
Johnson & Johnson JNJ, via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key ...
Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...
SPRING HOUSE, Pa., July 9, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA (R) ...
Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The ...
Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...
J&J has signed its latest Stelara patent settlement with Fresenius Kabi and Formycon, granting the biosimilar partners a U.S. license date for their drug beginning "no later than April 15, 2025," ...
55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results